LabCorp to offer Exact's colorectal cancer test
This article was originally published in Clinica
Executive Summary
Laboratory Corporation of America is to pay up to $75m for a five-year, exclusive licence to Exact Sciences' PreGen-Plus, a proprietary DNA-based noninvasive technology for the early detection of colorectal cancer in the average-risk population. After five years, LabCorp will have a non-exclusive licence for the life of the patents. The launch of the product is expected in first half of 2003.